GlassScriptPhysician profile
Nathan Shumway
NPI 1285616359
$6,430.66
in general payments reported to CMS, 2019-2025
32 companies · $527 in 2025
The $527 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $844 · 2020: $126 · 2021: $95.75 · 2022: $436 · 2023: $1,715 · 2024: $2,686 · 2025: $527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,298 · Consulting Fee: $1,713 · Travel and Lodging: $871 · Education: $47.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,297.59 |
| Consulting Fee | $1,712.50 |
| Travel and Lodging | $871.20 |
| Education | $47.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,877.76 | 2023-2024 | Imfinzi, Tagrisso |
| Stryker Corporation | $1,187.59 | 2023 | Invision, Prophecy, Inbone |
| E.R. Squibb & Sons, L.L.C. | $361.97 | 2021-2025 | Opdivo |
| Onmark, INC. | $269.25 | 2024 | |
| Amgen INC. | $252.49 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $215.50 | 2022-2024 | Fruzaqla |
| Genzyme Corporation | $188.59 | 2024 | |
| Gilead Sciences, INC. | $149.87 | 2021-2023 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $141.29 | 2024-2025 | Libtayo |
| Pfizer INC. | $133.96 | 2019-2025 | |
| Exelixis INC. | $129.53 | 2019 | |
| Emd Serono, INC. | $125.95 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.99 | 2024 | |
| G1 Therapeutics, INC. | $124.99 | 2022 | |
| Genmab U.S., INC. | $124.99 | 2024 | Epkinly |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immunogen, INC. | $124.99 | 2023 | Elahere |
| Janssen Biotech, INC. | $124.99 | 2019 | |
| Rigel Pharmaceuticals, INC. | $119.43 | 2019 | |
| Immunocore Limited | $112.38 | 2025 | Kimmtrak |
| Merck Sharp & Dohme LLC | $101.25 | 2023 | Keytruda |
| Abbvie INC. | $100.01 | 2019 | |
| Verastem, INC. | $88.87 | 2019 | |
| Kite Pharma, INC. | $46.17 | 2019 | |
| Johnson & Johnson Health Care Systems INC. | $38.40 | 2025 | Rybrevant, Erleada, Tremfya |
| Sobi, INC | $38.21 | 2025 | |
| Lilly USA, LLC | $33.25 | 2022 | |
| Genentech USA, INC. | $28.65 | 2025 | Polivy |
| Fennec Pharmaceuticals, INC. | $24.17 | 2024 | Pedmark |
| Puma Biotechnology, INC. | $17.95 | 2022 | |
| Array Biopharma INC | $13.04 | 2019 | |
| Clovis Oncology, INC. | $10.18 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Shumway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.